(Source: Business Wire)
The Cancer Immunotherapy Index of ten leading cancer immunotherapy
stocks has increased 80% during its first three months of measurement.
The CI Index as a whole trades for 10% of estimated future revenues. The
implied 1,000% possible increase is consistent with the 1,000% share
price increase of the CI Index company furthest along in FDA trials,
Dendreon (NASDAQ:DNDN). The share price increase followed Dendreon's
positive Phase III prostate cancer immunotherapy results during March
2009.
Two companies have lead the CI Index during the quarter in both growth
and potential growth. ImmunoCellular Therapeutics, Inc. (IMUC.OB) was 1st
in growth, and 2nd in remaining potential. Mentor Capital,
Inc. (PINK SHEETS:MNTR) was 3rd in growth and 1st
in potential market cap growth. In addition to ImmunoCellular
Therapeutics, Mentor Capital and Dendreon, the CI Index features
Oncothyreon (NASDAQ:ONTY), Antigenics (NASDAQ:AGEN), Biovest
International (PINK SHEETS:BVTI), Celldex Therapeutics (NASDAQ:CLDX),
Northwest Biotherapeutics (NWBO.OB), CEL -- SCI Corp. (AMEX:CVM), Generex
Biotechnology (NASDAQ:GNBT) as a proxy for its wholly-owned
immunotherapeutic subsidiary, Antigen Express. The Mentor Capital, Inc.
value substantially tracks the value of its major investee, Quantum
Immunologics, Inc., which is private.
In the cancer immunotherapy field, the goal is to train the patient's
immune system to recognize and attack cancer cells much the way the
immune system naturally attacks any microbe. If efficacy can be firmly
established, the slight temperature and feeling of tiredness
accompanying any immune response is infinitely preferable to the
debilitating effects of chemotherapy, radiation or surgeries. The weekly
public market progress of the companies in the cancer immunotherapy
sector can be followed in detailed updates of the Cancer Immunotherapy
Index presented at www.MentorCapital.com.
Forward Looking Statements, Safe Harbor and Risk Descriptions are
Incorporated by Reference from the MNTR Company Web Site above.
A service of YellowBrix, Inc.
